TG20, a Transgenically-Derived Anti-CD20 Monoclonal Antibody, Exhibits Enhanced Cytotoxicity Against Cells with Low Levels of CD20. By admin / 12/13/2011
Multicentre Phase I Study with an 8-Dose Regimen of Single Agent Anti-CD20 Monoclonal Antibody LFB-R603 in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL). By admin / 12/13/2011
LFB-R603, a Third-Generation Monoclonal Anti-CD20 Antibody, Displays Additive Antitumor Activity with Antileukemic Chemotherapeutic Agents in Mouse Xenograft Models. By admin / 12/13/2011
Comparison of Cell Lysis Mediated by LFB-R603 with That Mediated by Ofatumumab Against Cells Expressing Low Levels of CD20. By admin / 12/13/2011
